MPM BioImpact’s Acadia Pharmaceuticals ACAD Stock Holding History

MPM BioImpact’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-151,750	Closed	-$3.67M	–	38
2022 Q1	$3.67M	Buy	151,750 +26,750	+21%	+$647K	0.99%	30
2021 Q4	$2.92M	Buy	+125,000	New	+$2.51M	0.53%	30

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MPM BioImpact's ACAD Position: Q2 2022 in Review

MPM BioImpact sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 151,750 shares — an estimated $3.67M sold.

MPM BioImpact first reported a position in ACAD in Q4 2021 and held it in 2 quarters. The position peaked at $3.67M in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

MPM BioImpact reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
MPM BioImpact sold 151,750 Acadia Pharmaceuticals shares in Q2 2022, an estimated $3.67M.
MPM BioImpact first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 2 quarters.
MPM BioImpact's Acadia Pharmaceuticals position peaked at $3.67M in Q1 2022.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on MPM BioImpact's 13F filing for Q2 2022, filed 11 Aug 2022.